期刊
JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES
卷 11, 期 3, 页码 388-392出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/20009666.2021.1903133
关键词
Keytruda; pembrolizumab; Guillain barre syndrome; immune checkpoint inhibitor; neurological complications; PD 1 antibody
Immune checkpoint inhibitor-related neurotoxicity causing Guillain Barre Syndrome is rare, but can be fatal if not promptly diagnosed and managed. Prompt recognition and treatment of neurological autoimmune side effects is crucial with the increasing use of immunotherapy for cancer management.
Immune checkpoint inhibitor-related neurotoxicity causing Guillain Barre Syndrome is relatively uncommon. We discussed an 80-year-old patient with known systemic lupus erythematosus who presented with lower extremity weakness, areflexia and then progressed to respiratory muscle and upper extremity weakness after receiving immunotherapy with checkpoint inhibitors for metastatic bladder cancer. With the increasing use of immunotherapy for the management of cancer, awareness of neurological autoimmune side effects is essential. Immune checkpoint inhibitor-mediated GBS can be severe and fatal if not diagnosed promptly. The hospitalists, neurologists, and oncologists should be aware of neurotoxicity related to immune checkpoint inhibitor therapy requiring a multidisciplinary approach to patient care. Prompt initiation of immunosuppressive therapy is required for the management of immune checkpoint inhibitor-related neurotoxicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据